LFMD
LifeMD, Inc.
LFMD's outlook is improving, though it still trails on the overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over LFMD overall, supported by stronger fundamentals.
LFMD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Strong |
LFMD's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LFMD PE Valuation
LFMD has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
LFMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect LFMD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
LFMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.05 | +$0.11 |
| Q2 2026 | -$0.04 | +$0.16 |
| Q1 2026 | $0.06 | +$0.39 |
| Q4 2025 | $0.27 | +$0.80 |
| Q3 2025 | -$0.16 | +$0.48 |
| Q2 2025 | -$0.20 | +$0.50 |
| Q1 2025 | -$0.33 | +$0.41 |
| Q4 2024 | -$0.53 | +$0.17 |
LFMD lost $0.05 per share over the past year, a smaller loss than the year before, but its loss has widened in each of the last three quarters.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over LFMD on earnings quality, reporting a profit while its opponent remains loss making.
LFMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $44.6M | -26% |
| Q2 2026 | $47.3M | -24% |
| Q1 2026 | $50.2M | -24% |
| Q4 2025 | $7.1M | -89% |
| Q3 2025 | $60.2M | +13% |
| Q2 2025 | $62.2M | +23% |
| Q1 2025 | $65.7M | +49% |
| Q4 2024 | $64.3M | +43% |
LFMD's revenue has slid since its 2025 peak: $45M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | -6.7 points |
| Q2 2026 | -15% | -14 points |
| Q1 2026 | -18% | -22 points |
| Q4 2025 | -88% | -90 points |
| Q3 2025 | -3.3% | +5.5 points |
| Q2 2025 | -1.5% | +11 points |
| Q1 2025 | 3.9% | +18 points |
| Q4 2024 | 1.6% | +6.4 points |
LFMD's operating margin was −10% last quarter, down 6.7 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over LFMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over LFMD on profitability, with a higher operating margin.
LFMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.1M | -$176K |
| Q2 2026 | -$7M | -189% |
| Q1 2026 | $339.4K | -88% |
| Q4 2025 | -$3.4M | -356% |
| Q3 2025 | -$944.4K | -116% |
| Q2 2025 | $7.8M | +101% |
| Q1 2025 | $2.9M | -41% |
| Q4 2024 | $1.3M | -76% |
LFMD's free cash flow was −$11M over the past year, against $11M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over LFMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
LFMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +394K shares |
| 1 year | +4.4% | +2M shares |
| 3 years | +40% | +13.7M shares |
| 5 years | +81% | +21.5M shares |
| Available history | +387% | +38.3M shares |
LFMD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2025 | $270,000 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LFMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -9.6x | Net Cash |
LFMD has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
LFMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.5 | Oversold |
| Stochastic | 10.1 | Oversold |
LFMD's weekly RSI is 27 (oversold) and its Stochastic is 10 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LFMD PE vs Healthcare Sector
| Metric | LFMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LFMD has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LFMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.39 | 31% below |
| 20 week MA | $3.14 | 47% below |
| 50 week MA | $3.54 | 53% below |
| 100 week MA | $5.40 | 69% below |
| 200 week MA | $5.43 | 69% below |
LFMD is in a downtrend: it's below all five of its weekly moving averages, and 69% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over LFMD on trend strength, trading above more of its moving averages.
LFMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.65 | $7.84 | +1106% |
| 2021 | $7.84 | $4.32 | -45% |
| 2022 | $4.32 | $2.05 | -53% |
| 2023 | $2.05 | $8.29 | +304% |
| 2024 | $8.29 | $5.22 | -37% |
| 2025 | $5.22 | $3.50 | -33% |
| 2026 YTD | $3.50 | $1.66 | -53% |
LFMD's yearly returns have swung widely, from +1106% in 2020 to −53% in 2022. It's down 53% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LFMD on returns for 2026, with the stronger performance.